Please login to the form below

Not currently logged in
Email:
Password:

Novartis US appeals halt generic Famvir

Novartis says that a US court halted Israeli-based Teva's sale of a generic version of its Famvir genital herpes treatment

Novartis has said that that a US court has halted Israeli-based Teva's sale of a generic version of its Famvir (famciclovir) genital herpes treatment.

The Swiss-headquartered company said the injunction by the US Court of Appeals for the Federal Circuit was issued on 8 September, two days after a district court in New Jersey denied Novartis' motion to stop Israel's Teva from marketing its version of the drug.

The injunction requires Teva to submit a response by 11 September 2007, Novartis revealed in a company statement.

Novartis shares were down 0.4 per cent at CHF 63.25 (USD 53.27) on the Zurich stock exchange on 10 September 2007.

10th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics